Compare SHC & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | ADMA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.7B |
| IPO Year | 2020 | N/A |
| Metric | SHC | ADMA |
|---|---|---|
| Price | $17.77 | $19.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $17.80 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | 0.20 | ★ 0.86 |
| Revenue | ★ $1,150,379,000.00 | $488,559,000.00 |
| Revenue This Year | $6.41 | $22.19 |
| Revenue Next Year | $5.89 | $23.71 |
| P/E Ratio | $90.62 | ★ $22.52 |
| Revenue Growth | 2.67 | ★ 27.63 |
| 52 Week Low | $9.53 | $13.50 |
| 52 Week High | $17.83 | $25.67 |
| Indicator | SHC | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 53.64 |
| Support Level | $16.55 | $18.33 |
| Resistance Level | $17.83 | $19.94 |
| Average True Range (ATR) | 0.29 | 0.60 |
| MACD | 0.07 | -0.19 |
| Stochastic Oscillator | 92.50 | 36.42 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.